October 27, 2018

Glycanostics Receives the Prestigious Horizon 2020 “Seal of Excellence”

The European Commission awarded Glycanostics the prestigious Seal of Excellence for its revolutionary prostate cancer early diagnostic tests. This project was submitted under the Horizon 2020 Programme for Research and Innovation 2014-2020, and received the highest scores for its proposal in the extremely competitive evaluation process. The European Commission has a rigorous evaluation system—with a panel of international, independent experts—based on three criteria: excellence, impact and quality, and efficiency of implementation.

Jan Tkac, Сo-Founder and Executive Manager of Glycanostics Ltd., comments:

“It feels really great to be ranked among the best projects by the leading EU industry experts! And again, it's another confirmation that our products are innovative, meet market needs, and have an efficient business model!”

The Glycanostics’ team plans to continue with new H2020 submissions. Now, with the Seal of Excellence, the company's chances are significantly higher! This award also increases the investment appeal of the company as the Seal is a label of quality which identifies promising projects and recommends them for funding from alternative sources, be they public or private, regional or national, European or international.

Horizon 2020

Horizon 2020 is the biggest EU Research and Innovation Programme ever.  The program identifies and supports breakthroughs, discoveries, and world-firsts by taking great ideas from the lab to the market.  The Seal of Excellence is a “high-quality” label awarded to those projects submitted to Horizon 2020 which were deemed deserving of funding, but did not receive it due to budget limitations. The Seal of Excellence Certificate rewards the best unfunded proposals with the ability to approach alternative regional, national, private, or public funding sources. In addition, it helps funding bodies wanting to invest in the most promising proposals (including national & regional authorities through European Structural & Investment Funds) to identify these projects more easily.

Other News

June 22, 2021

Glycanostics meet the President of the EC Mrs. Ursula von der Leyen

On Monday, June, 21st our CEO Eva Kovacova (on the right) together with CSO Jan Tkac (on the left) had a great honour to introduce the company Glycanostics to the President of the EC Mrs. Ursula von der Leyen, our Prime Minister Mr. Eduard Heger and Vice-President of the EC Mr. Maros Sefcovic. As one out of seven selected innovative companies, we presented our highly accurate, non-invasive, and early-stage cancer diagnostics that can help save the lives of millions of people worldwide.

October 18, 2019

A highly-prestigious award for a Glycanostics co-founder

ESET launched a prestigious ESET Science Award for exceptional scientists

October 3, 2019

International Patent Application No. PCT/EP2019/057386

Means and methods for glycoprofiling of a protein

August 31, 2019

Glycanostics succesfully finished Horizon 2020 SME Instrument 1 Grant

Glycanostics successfully finished the first phase of SME Instrument

December 10, 2018

Glycanostics Wins Horizon 2020 Grant

After receiving the prestigious “Seal of Excellence” on October 23, the next submission to the Horizon 2020 Programme, won a € 50 000 grant.

October 24, 2018

Glycanostics Wins TOP-6 Best Startups in Central Europe

Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.

August 14, 2018

Glycanostics Applies for Innovation-Securing Patent

The application covering Glycanostics' diagnostic method is currently filed in two patent offices in Europe and Luxemburg.

July 27, 2018

Glycanostics wins the European Research Council Grant

Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.

June 14, 2018

Glycanostics Takes 3rd Place in Vodafone’s Idea of The Year Competition

The competition's objectives are to actively support innovative projects with high market potential

May 1, 2018

Glycanostics PCa DX kit showed 95+% accuracy on the pre-clinical validation

In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.

November 30, 2017

Jan Tkac and Tomas Bertok – Scientists of the year award winners - establish Glycanostics to bring their revolutionary innovation to cancer diagnostics market

Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.